Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2014-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2013-4232PMID 24628556PMCID PMC4037733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A specific and sensitive assay for blood levels of glycated CD59: A novel biomarker for diabetes

  2013cited by this paper
• Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction

  2012cited by this paper
• Transcriptome Analysis of Human Diabetic Kidney Disease

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients.

  2010cited by this paper
• Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily

  2010cited by this paper
• Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study.

  2010cited by this paper
• Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes

  2010cited by this paper
• Instrumenting the health care enterprise for discovery research in the genomic era.

  2009cited by this paper
• Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex

  2009cited by this paper
• Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c.

  2008cited by this paper
• Translating the A1C Assay Into Estimated Average Glucose Values

  2008cited by this paper
• Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003).

  2008cited by this paper
• The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program

  2007cited by this paper
• Obesity and diabetes in the developing world--a growing challenge.

  2007cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study.

  2005cited by this paper
• Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects

  2005cited by this paper
• Complement and complement regulatory proteins as potential molecular targets for vascular diseases.

  2004cited by this paper
• Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation.

  2004cited by this paper
• Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes.

  2004cited by this paper
• Association between mannose-binding lectin and vascular complications in type 1 diabetes.

  2004cited by this paper
• Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility.

  2003cited by this paper
• The spectrum of neuropathy in diabetes and impaired glucose tolerance

  2003cited by this paper
• Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex.

  2003cited by this paper
• Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy.

  2002cited by this paper
• Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.

  2001cited by this paper
• Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

  2001cited by this paper
• Molecular basis for a link between complement and the vascular complications of diabetes.

  2000cited by this paper
• Local activation of the complement system in endoneurial microvessels of diabetic neuropathy

  2000cited by this paper
• Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

  1999cited by this paper
• Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Binding of human and rat CD59 to the terminal complement complexes

  1997cited by this paper
• The Transient Pore Formed by Homologous Terminal Complement Complexes Functions as a Bidirectional Route for the Transport of Autocrine and Paracrine Signals across Human Cell Membranes

  1996cited by this paper
• Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells

  1994cited by this paper
• Diabetes Control and Complications Trial (DCCT): Update

  1990cited by this paper
• Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.

  1990cited by this paper
• Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

  1990cited by this paper

• Glycated CD59: an emerging biomarker of diabetic nephropathy associated with microalbuminuria, tubular damage, and complement activation

  2026cites this paper
• Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma

  2025cites this paper
• Complement at the crossroads of inflammation and metabolism: implications for diabetes and metabolic functions.

  2025cites this paper
• The Relationship of the Plasma Glycated CD59 Level with Microvascular Complications in Diabetic Patients and Its Evaluation as a Predictive Marker

  2025cites this paper
• Immune cell dysfunction: A critical player in development of diabetes complications.

  2025cites this paper
• Regulation of the terminal complement cascade in adipose tissue for control of its volume, cellularity, and fibrosis

  2025cites this paper
• The Role of Complement Activation in Diabetic Nephropathy: Current Insights and Future Directions

  2025cites this paper
• The Complement System as a Therapeutic Target in Retinal Disease

  2024cites this paper
• Plasma Glycated CD59 and Gestational Diabetes Mellitus: A Systematic Review

  2024cites this paper
• Proteomic Profiling of Endothelial Cell Secretomes After Exposure to Calciprotein Particles Reveals Downregulation of Basement Membrane Assembly and Increased Release of Soluble CD59

  2024cites this paper
• Glycated CD59 is a potential biomarker for gestational diabetes mellitus

  2024cites this paper
• Testing AI Predictions that Hyperglycemia-Induced Non-Enzymatic Glycation of Immune System Proteins Impairs Diabetic Immunity

  2024cites this paper
• The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening

  2023cites this paper
• Improved meta-analysis pipeline ameliorates distinctive gene regulators of diabetic vasculopathy in human endothelial cell (hECs) RNA-Seq data

  2023cites this paper
• Algae: A Robust Living Material Against Cancer

  2023cites this paper
• The Belgian Diabetes in Pregnancy Follow-Up Study (BEDIP-FUS): A Multi-Centric Prospective Cohort Study on the Long-Term Metabolic Risk across Different Degrees of Gestational Glucose Intolerance: Methodology and Design

  2023cites this paper
• The Diagnostic Accuracy of Second Trimester Plasma Glycated CD59 (pGCD59) to Identify Women with Gestational Diabetes Mellitus Based on the 75 g OGTT Using the WHO Criteria: A Prospective Study of Non-Diabetic Pregnant Women in Ireland

  2022cites this paper
• The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study

  2022cites this paper
• Novel Insight into the Mechanisms of the Bidirectional Relationship between Diabetes and Periodontitis

  2022cites this paper
• Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes.

  2021cites this paper
• Complement, a Therapeutic Target in Diabetic Kidney Disease

  2021cites this paper
• Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes

  2021cites this paper
• Conventional and Unconventional Mechanisms by which Exocytosis Proteins Oversee β-cell Function and Protection

  2021cites this paper
• Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes—A Scoping Review

  2021cites this paper
• Monitoring motherhood: Monitoring and optimizing glycaemia in women with pre-existing diabetes in pregnancy

  2021cites this paper
• Early markers of gestational diabetes mellitus: what we know and which way forward?

  2021cites this paper
• Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

  2021cites this paper
• Novel biochemical markers of glycemia to predict pregnancy outcomes in women with type 1 diabetes

  2021cites this paper
• Erythrocytes Reveal Complement Activation in Patients with COVID-19

  2020cites this paper
• Plasma Glycated CD59 Predicts Early Gestational Diabetes and Large for Gestational Age Newborns.

  2020cites this paper
• Associations of dicarbonyl stress with complement activation: the CODAM study

  2020cites this paper
• Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) – protocol for prospective cohort study

  2020cites this paper
• A cryptic non–GPI‐anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic β‐cells by interaction with SNARE proteins

  2019cites this paper
• Role of complement in diabetes.

  2019cites this paper
• Identification of urinary biomarkers for the prediction of gestational diabetes mellitus in early second trimester of young gravidae based on iTRAQ quantitative proteomics.

  2018cites this paper
• The diabetes pandemic and associated infections: suggestions for clinical microbiology

  2018cites this paper
• Stability and bioactivity of chitosan as a transfection agent in primary human cell cultures: A case for chitosan-only controls.

  2018cites this paper
• Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.

  2017cites this paper
• Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance

  2017influential citation
• Diabetes mellitus y su impacto en la etiopatogenia de la sepsis

  2017cites this paper
• Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.

  2017cites this paper
• Diabetic retinopathy and dysregulated innate immunity

  2017cites this paper
• The role of complement system in adipose tissue-related inflammation

  2016cites this paper
• Complement and Complement Regulatory Proteins in Diabetes

  2015cites this paper
• Role of complement and complement regulatory proteins in the complications of diabetes.

  2015cites this paper
• The complement system in human cardiometabolic disease.

  2014cites this paper
• Glycated CD59 as a Novel Biomarker of Diabetic Nephropathy: Links to Microalbuminuria, Tubular Injury, and Complement Activation

  year unknowncites this paper